D3-binding molecules and uses thereof
US-2024376194-A1 · Nov 14, 2024 · US
US9766252B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9766252-B2 |
| Application number | US-201314386269-A |
| Country | US |
| Kind code | B2 |
| Filing date | Mar 13, 2013 |
| Priority date | Mar 22, 2012 |
| Publication date | Sep 19, 2017 |
| Grant date | Sep 19, 2017 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
An embodiment of the invention is a peptide comprising four domains, wherein domain I consists of thioctyl or monocytl, domain II consists of 2 to 3 positively charged amino acids selected from the group consisting of lysine and arginine, domain III consists of a dimeric ethylene unit; and domain IV comprises the peptide with SEQ ID No. 1 or a sequence having at least 90% identity to SEQ ID No. I. The peptide is preferably attached to a gold nanostructure, preferably a gold nanorod to provide an EFGR kit. An EFGR detection kit of the invention employs a gold nanostructure attached to a peptide sequence, the peptide sequence includes a binding sequence with an affinity toward EGFR, a ligand bound to gold atoms of the nanorod, a positively charged amino acid that maintains activity of the binding sequence, and a unit that increases hydrophilicity of the peptide sequence.
Opening claim text (preview).
The invention claimed is: 1. A peptide comprising four domains, wherein domain I consists of thioctyl or monothiol, domain II consists of 2 to 3 positively charged amino acids selected from the group consisting of lysine and arginine, domain III consists of a dimeric ethylene unit; and domain IV comprises the peptide with SEQ ID No. 1. 2. The peptide of claim 1 , wherein domain I consists of thioctyl. 3. The peptide of claim 2 , wherein domain II consists of 2 molecules of lysine. 4. The peptide of claim 1 , attached to a gold nanostructure. 5. The peptide of claim 4 , wherein the gold nanostructure comprises a gold nanorod. 6. An epidermal growth factor receptor (EGFR) detection kit comprising a solution of peptides attached to the gold nanorod according to claim 5 . 7. An epidermal growth factor receptor (EGFR) detection kit comprising a solution of peptides attached to gold nanorods according to claim 4 . 8. An epidermal growth factor receptor (EGFR) detection kit comprising: a gold nanostructure attached to a peptide comprising four domains, wherein domain I consists of thioctyl or monothiol, domain II consists of 2 to 3 positively charged amino acids selected from the group consisting of lysine and arginine, domain III consists of a dimeric ethylene unit and domain IV comprises the peptide with SEQ ID No. 1. 9. The EGFR detection kit of claim 8 , wherein the positively charged amino acids consists of 2 or 3 molecules of lysine. 10. An epidermal growth factor receptor (EGFR) detection kit comprising a solution of peptides attached to the gold nanostructure according to claim 4 .
Peptides being immobilised on, or in, an inorganic carrier · CPC title
Intracellular protein regulatory factors and their receptors, e.g. including ion channels · CPC title
Nanoparticles · CPC title
Epidermal growth factor [EGF] (urogastrone) · CPC title
having 12 to 20 amino acids (gastrins C07K14/595; somatostatins C07K14/655; melanotropins C07K14/68) · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.